While GLP-1 suppresses glucagon secretion at euglycemia, but not during hypoglycemia [18], GIP stimulates glucagon secretion at euglycemia, but not during hyperglycemia [19], being one of the reasons behind the apathy for GIP-based therapies for T2D. The gene discussed is GCG; the disease is Hyperglycemia.